Lactoferrin for Iron Absorption

Verdict: Promising for iron, but institutions stay silent

Oral lactoferrin appears to match or modestly beat ferrous sulfate at raising iron status with fewer gut side effects, but the evidence comes from small, mostly single-center trials and no major clinical body endorses it, so it rates only preliminary (Tier B) support.

B 🟡 B Preliminary Evidence Published

🔬Why this grade7-layer evidence engine

The clinical literature is consistently positive. Four meta-analyses and systematic reviews covering more than 4,800 people found oral bovine lactoferrin equaled or outperformed ferrous sulfate: a 19-trial pooled analysis favored lactoferrin for hemoglobin (PMID 38291525), an 11-trial analysis showed higher serum iron and ferritin (PMID 35276902), a pregnancy meta-analysis raised hemoglobin by about 0.77 g/dL (PMID 29059584), and a pediatric review reached the same conclusion (PMID 37661669). All reported fewer gastrointestinal side effects.

The grade stays at preliminary because the body of work is thin where it counts. The trials are mostly small and single-center, several come from research groups with potential dairy-industry ties, and the only direct iron-absorption study (a stable-isotope crossover in 25 infants) showed the benefit depends on form: iron-unsaturated apo-lactoferrin raised fractional absorption, while iron-saturated holo-lactoferrin behaved like ferrous sulfate. Most retail products do not disclose which form they contain.

Institutions are notably silent. The US FDA has issued GRAS no-questions letters and EFSA cleared bovine lactoferrin as a novel food, but both rulings concern food-ingredient safety, not any authorized iron-absorption or anti-anemia health claim; the NHS and WHO take no position. No major clinic (Mayo, Cleveland Clinic, Harvard, NIH ODS) mentions lactoferrin for iron, and gastroenterology guidance still names ferrous sulfate the preferred oral iron. That gap between encouraging trials and unconvinced clinical bodies is exactly what a Tier B verdict reflects.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.66
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published
Confidence
81%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L5 Clinical bodiesAuthoritative stance
0.50
L3 MechanismPlausibility
0.65
L11 AI re-checkIndependent read
0.65
L2 PubMedPrimary literature
0.85
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.657
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (3 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

The effectiveness of oral bovine lactoferrin compared to iron supplementation in patients with a low hemoglobin profile: A systematic review and meta-analysis of randomized clinical trials
PMID: 38291525 2024 統合分析 n = 2,992
Finding: Across 19 RCTs (n=2992), oral bovine lactoferrin produced significantly greater Hb improvement vs ferrous sulfate (SMD -0.81, 95% CI -1.21 to -0.42, p<0.0001); longest-duration subgroup SMD 1.04 (p=0.004). Lactoferrin also showed fewer GI side effects and higher compliance.
Effect size: SMD -0.81 favoring lactoferrin over ferrous sulfate for Hb
View on PubMed
Comparative Effects between Oral Lactoferrin and Ferrous Sulfate Supplementation on Iron-Deficiency Anemia: A Comprehensive Review and Meta-Analysis of Clinical Trials
PMID: 35276902 2022 統合分析 n = 1,262
Finding: Lactoferrin produced greater improvements than ferrous sulfate in serum iron (WMD +41.44 ug/dL, p<0.00001), ferritin (WMD +13.60 ng/mL, p=0.003), and hemoglobin (WMD +11.80 g/dL [reported unit], p<0.00001); GI tolerability was significantly better.
Effect size: WMD serum iron +41.44 ug/dL; ferritin +13.60 ng/mL favoring lactoferrin
View on PubMed
Lactoferrin or ferrous salts for iron deficiency anemia in pregnancy: A meta-analysis of randomized trials
PMID: 29059584 2017 統合分析 n = 600
Finding: Across 4 trials (n=600 pregnant women), lactoferrin favored over ferrous sulfate (MD +0.77 g/dL, 95% CI 0.04-1.55, p=0.04); moderate anemia subgroup MD +0.68 (95% CI 0.53-0.83, p<0.00001); fewer GI side effects with lactoferrin.
Effect size: MD Hb +0.77 g/dL favoring lactoferrin
View on PubMed
Iron Absorption is Greater from Apo-Lactoferrin and is Similar Between Holo-Lactoferrin and Ferrous Sulfate: Stable Iron Isotope Studies in Kenyan Infants
PMID: 33188436 2020 Other n = 25
— See PubMed for details
View on PubMed
Lactoferrin as treatment for iron-deficiency anemia in children: a systematic review
PMID: 37661669 2023 系統性回顧
Finding: Across pediatric RCTs, most studies report significantly greater Hb rise with lactoferrin (alone or with elemental iron) vs iron alone or placebo; ferritin also higher; fewer GI side effects. Authors conclude Lf is a superior pediatric IDA treatment.
Effect size: qualitative - favors lactoferrin
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
FDA has no questions source↗
L4b EU EFSA
Supportive
L4d TW TFDA / 衛福部
Supportive
第(八)類 營養添加劑 編號08112 乳鐵蛋白 — 自中華民國一百十二年一月一日施行 source↗
L5a NIH Office of Dietary Supplements
Cautious
L5e Specialty Society (condition-mapped)
Not addressed
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-iron-absorption-INT-lactoferrin-001 繁體中文版 →